🔎 Trials Near Me

መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › Ohio › Columbus

በColumbus፣ OH ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 28 ጥናቶች በColumbus እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • Riverside Methodist Hospital, Columbus
  • እና 8 ተጨማሪ
እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • እና 8 ተጨማሪ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Study Site 104, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT07582432

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT04269902

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 75 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07685717

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The Ohio State University, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Research Site, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The James Cancer Hospital and Solove Research Institute, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦገስ 2026 · NCT07734038

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • OSU Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The Ohio State University Wexner Medical Center, Columbus
እድሜ ከ13 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ጁላይ 2026 · NCT06708897

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 2 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሜይ 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University, Columbus
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

ተሳታዮችን በመፈለግ ላይደረጃ 4
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

ተሳታዮችን በመፈለግ ላይደረጃ 4
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ፌብሩ 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ፌብሩ 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University - The James Cancer Hospital, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The Ohio State University /ID# 230439, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጃንዩ 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጃንዩ 2026 · NCT06043674

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ዲሴም 2025 · NCT06757647

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05780034

HPC Offered for PRESERVE Expansion

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • The Ohio State University Medical Center, Columbus
እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2025 · NCT07145411

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2022 · NCT04502394

በሌሎች ከተሞች ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ጥናቶች

በColumbus ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።